FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology, namely to clinical-laboratory prediction of neuropathological conditions. By clinical, virological and genetic examination authors suggest additionally to determine in whole blood and CNS of child DNA of human herpes virus type 6, genotypes A, B, their quantitative characteristics with determination of concentration of 104 and more DNA copies/ml, and if human genotype 6 virus of genotype A is detected, an unfavourable pro-mediated course is predicted, and if observing human herpes virus type 6 genotype B, a favourable outcome of the disease is predicted.
EFFECT: invention can be used for prediction of clinical course of organic CNS affection associated with combined herpes virus infections in children.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR THE COMBINED INFECTION IN CHILDREN WITH ACUTE RESPIRATORY INFECTIONS | 2019 |
|
RU2706126C1 |
| METHOD FOR PREDICTING HUMAN TYPE 6 HERPES VIRUS INFECTION IN CHILDREN | 2018 |
|
RU2695323C1 |
| METHOD FOR ASSESSMENT OF ACTIVITY OF INFECTION CAUSED BY HERPES TYPE 4, 5 AND 6 IN CHILDREN | 2016 |
|
RU2639593C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CNS ORGANIC LESIONS IN CHILDREN DURING THE ACUTE PERIOD | 2017 |
|
RU2648215C1 |
| METHOD FOR ASSESSING SEVERITY OF MENINGOENCEPHALITIS OF HERPETIC AETIOLOGY IN HIV INFECTION | 2017 |
|
RU2691710C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LATENT AND ACTIVE FORMS OF HHV-6 INFECTION IN CHILDREN | 2023 |
|
RU2817089C1 |
| METHOD FOR EVALUATION OF EFFICIENCY OF TYPE 6 HUMAN HERPES VIRUS INFECTION THERAPY IN CHILDREN | 2016 |
|
RU2646472C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF HERPES VIRUS MIXED INFECTION | 2020 |
|
RU2739854C1 |
| METHOD OF DETECTING RENAL TRANSPLANT INFECTION | 2019 |
|
RU2728324C1 |
| METHOD FOR PREDICTING TRANSFORMATION OF CHRONIC DISSEMINATED ENCEPHALOMYELITIS IN MULTIPLE SCLEROSIS IN CHILDREN | 2020 |
|
RU2740243C1 |
